Edgewise Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow JonesDec 17 23:52 · Ratings

Edgewise Therapeutics Analyst Ratings

BenzingaDec 17 23:41 · Ratings

Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50

Futu NewsDec 17 22:34 · Ratings

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Zacks Dec 17 21:30

A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $50 to $50

Futu NewsDec 17 21:00 · Ratings

Promising Outlook for Edgewise Therapeutics: Buy Rating Reaffirmed With Increased Price Target

TipRanksDec 17 04:55 · Ratings